Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMAB017 in Advanced Malignant Solid Tumors
NCT06933069Phase 1Recruiting
- Sponsor
- Taizhou Mabtech Pharmaceutical
- Start
- Jun 2025
- Primary completion
- May 2027
- Modality
- Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CMAB017 in solid tumor, sponsored by Taizhou Mabtech Pharmaceutical. Primary endpoints: Dose Limiting Toxicities at 12 weeks and Maximal Tolerated Dose at 12 weeks. Started Jun 2025; status: recruiting.
02
Drugs
CMAB017
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06933069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06933069.